<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2412246477
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INNOHEP 10000 ANTI-XA IU-ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TINZAPARIN SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        543.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Leo Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Leo Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Leo Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Properties<br />Tinzaparin sodium is a low molecular weight heparin<br />produced by enzymatic depolymerization of<br />conventional heparin.<br />The molecular mass is between 1,000 and 14,000 dalton,<br />with a peak maximum molecular mass of approx. 4,500<br />dalton. Tinzaparin sodium is an anti-thrombotic agent.<br />innohep&reg; has a bioavailability of about 90% following<br />subcutaneous injection. The absorption half-life is 200<br />minutes, peak plasma activity being observed after<br />4&ndash;6 hours.<br />The elimination half-life is about 80 minutes. Tinzaparin<br />sodium is eliminated, primarily with the urine, as<br />unchanged drug.<br />The pharmacokinetics/pharmacodynamics of innohep&reg;<br />are monitored by anti-Xa activity. There is a linear doseresponse<br />relationship between plasma activity and the<br />dose administered.<br />The biological activity of innohep&reg; is expressed in<br />international units anti-Xa.<br />Indications<br />Treatment of deep-vein thrombosis and pulmonary<br />embolism.<br />Prevention of postoperative deep-vein thrombosis in<br />patients undergoing general and orthopaedic surgery.<br />Prevention of clotting in in-dwelling intravenous lines<br />for extracorporeal circulation and haemodialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contraindications<br />Known hypersensitivity to any of the constituents.<br />The 20,000 IU anti-Xa/ml formulation of innohep&reg;<br />contains sodium metabisulphite, which may cause<br />allergic reactions, including anaphylaxis in predisposed<br />patients. In the remaining formulations without sulphite,<br />this risk does not exist.<br />Other contraindications are generalized or local<br />haemorrhagic tendency. Uncontrolled severe<br />hypertension. Acute cerebral insults. Septic<br />endocarditis.<br />For vials only:<br />innohep&reg; vials contain 10 mg/ml of the preservative<br />benzyl alcohol. These formulations must not be given to<br />premature babies and neonates due to the risk of<br />gasping syndrome.<br />Special precautions<br />innohep&reg; should be given with caution to patients with<br />hepatic insufficiency. Precaution is recommended in<br />the treatment of patients with severe renal impairment<br />(creatinine clearance &lt; 30 ml/min).<br />Precaution is recommended in the treatment of elderly<br />patients with renal impairment. Renal function should<br />be assessed and in patients with severe renal<br />impairment (creatinine clearance &lt; 30 ml/min),<br />monitoring of anti-factor Xa activity should be<br />considered.<br />innohep&reg; should not be administered by intramuscular<br />injection due to risk of local haematoma formation.<br />Patients receiving innohep&reg; concurrently with spinal or<br />epidural anaesthesia should be closely monitored for<br />signs or symptoms of neurological injury.<br />Interactions<br />Concomitant administration of other drugs affecting<br />haemostasis, e.g. vitamin K antagonists and dextran,<br />may enhance the anticoagulant effect of innohep&reg;.<br />Use during Pregnancy and Lactation<br />Data on a number (637) of exposed pregnancies<br />indicate no additional risk of tinzaparin on pregnancy or<br />on the health of the foetus / new-born child. No<br />transplacental passage was demonstrated in two (2)<br />clinical studies. Data from sequential pharmacokinetic<br />monitoring in 55 pregnancies suggest that<br />pharmacokinetic properties of tinzaparin do not differ<br />from the non-pregnant state.<br />Tinzaparin is not recommended for use in pregnant<br />women with prosthetic heart valves.<br />Caution should be exercised when prescribing tinzaparin to<br />pregnant women.<br />There are no data available concerning lactation.<br />For vials only:<br />Cases of &quot;Gasping Syndrome&quot; have occurred in<br />premature infants when large amounts of benzyl alcohol<br />have been administered (99-404 mg/Kg/day). Despite the<br />low content of benzyl alcohol in the vials (10 mg per ml),<br />as it may cross the placenta the use of innohep&reg;<br />formulations containing benzyl alcohol is not<br />recommended during pregnancy.<br />Incompatibilities<br />innohep&reg; is compatible with isotonic sodium chloride<br />(9 mg/ml) or isotonic glucose (50 mg/ml). It should not be<br />admixed with other infusion fluids.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage<br />Treatment of DVT and PE:<br />The recommended dose is 175 IU anti-Xa/kg bodyweight<br />s.c. once daily.<br />Thromboprophylaxis in patients with moderate risk of<br />thrombosis (general surgery):<br />On the day of operation 3,500 IU anti-Xa s.c. 2 hours<br />before surgery and postoperatively once daily 3,500 IU<br />anti-Xa for 7&ndash;10 days.<br />Thromboprophylaxis in patients with high risk of<br />thrombosis (e.g. total hip replacement):<br />On the day of operation 4,500 IU anti-Xa s.c. 12 hours<br />before surgery or 50 IU anti-Xa/kg body-weight s.c.<br />2 hours before surgery and then once daily until the<br />patient has been mobilized.<br />For short-term haemodialysis (less than 4 hours):<br />A bolus dose of 2,000&ndash;2,500 IU anti-Xa into the arterial<br />side of the dialyser (or intravenously) at the beginning of<br />dialysis.<br />Long-term haemodialysis (more than 4 hours):<br />A bolus dose of 2,500 IU anti-Xa into the arterial side of<br />the dialyser (or intravenously) at the beginning of<br />dialysis, followed by an infusion of 750 IU anti-Xa /hour.<br />Dose adjustment: Increase or decrease of the bolus<br />dose, if required, can be made in steps of 250&ndash;500 IU<br />anti-Xa until a satisfactory response is obtained.<br />Elderly:<br />Renal function should be assessed with e.g. the<br />Cockcroft-Gault formula to estimate creatinine<br />clearance levels.<br />No dose reduction is needed in elderly patients with<br />normal renal function. (See Special precautions).<br />Renal impairment:<br />No dose reduction is needed in patients having<br />creatinine clearance levels down to 20 ml/min.<br />However, precaution is recommended when treating<br />patients with severe renal impairment (creatinine<br />clearance &lt; 30 ml/min). (See Special precautions).</p><p>Overdose<br />An overdose of innohep&reg; may be complicated by<br />haemorrhage. At recommended doses there should be<br />no need for an antidote, but in the event of accidental<br />administration of an overdose, the effect of innohep&reg;<br />can be reversed by intravenous administration of 1%<br />protamine sulphate solution.<br />The dose of protamine sulphate required per<br />neutralization should be accurately determined by<br />titrating with the plasma of the patient. As a rule, 1 mg<br />of protamine sulphate neutralizes the effect of 100 IU<br />anti-Xa of tinzaparin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Adverse effects<br />innohep&reg; is safe with regard to bleeding risks, when<br />applied at the doses recommended, provided that<br />patients with increased bleeding potential (bleeding<br />disorders, severe thrombocytopenia) are excluded or<br />treated with special care.<br />Priapism and skin necrosis have been reported in only<br />a few cases.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Storage condition<br />Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>10 Vials of 2 ml<br />Tinzaparin sodium 10,000 IU anti-Xa/ml, preserved with<br />benzyl alcohol (10 mg/ml).<br />Tinzaparin sodium 20,000 IU anti-Xa/ml, preserved with<br />benzyl alcohol (10 mg/ml), stabilized with sodium<br />metabisulphite.<br />10 Pre-filled syringes with needle safety device of<br />0.25ml, 0.35ml or 0.45ml<br />Tinzaparin sodium 10,000 IU anti-Xa/ml.<br />2 Pre-filled syringes with needle safety device of 0.5ml,<br />0.7ml or 0.9ml<br />Tinzaparin sodium 20,000 IU anti-Xa/ml, stabilized with<br />sodium metabisulphite.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10 Vials of 2 ml
Tinzaparin sodium 10,000 IU anti-Xa/ml, preserved with
benzyl alcohol (10 mg/ml).
Tinzaparin sodium 20,000 IU anti-Xa/ml, preserved with
benzyl alcohol (10 mg/ml), stabilized with sodium
metabisulphite.
10 Pre-filled syringes with needle safety device of
0.25ml, 0.35ml or 0.45ml
Tinzaparin sodium 10,000 IU anti-Xa/ml.
2 Pre-filled syringes with needle safety device of 0.5ml,
0.7ml or 0.9ml
Tinzaparin sodium 20,000 IU anti-Xa/ml, stabilized with
sodium metabisulphite.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder: LEO Pharma A/S, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in October 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>الخصائص: </strong></p><p dir="RTL">تينزابارين الصوديوم هو هيبارين منخفض الوزن الجزيئي، تنتجه إزالة البلمرة الإنزيمية للهيبارين التقليدي.</p><p dir="RTL">الكتلة الجزيئية تتراوح ما بين 1000 و 14000 دالتون، مع كتلة جزيئية بذروة قصوى تبلغ 4500 دالتون تقريباً. تينزابارين الصوديوم هو عامل مضاد للجلطات.</p><p dir="RTL"><strong>لإنّوهيب<sup>&reg;</sup></strong> التوافر البيولوجي بحوالي 90% بعد الحقن تحت الجلد. امتصاص نصف العمر هو 200 دقيقة. وقد لوحظ ذروة نشاط البلازما بعد 4-6 ساعات.</p><p dir="RTL">نصف عمر التخلص هو حوالي 80 دقيقة. يتم التخلص من تينزابارين الصوديوم، في المقام الأول مع البول، كعقار غير متغير.</p><p dir="RTL">لقد تم رصد حرية ومبحث تأثير الدواء لدى <strong>إنّوهيب<sup>&reg;</sup> </strong>بواسطة أنشطة مضاد &ndash; إكس إيه. ووجد أن هنالك علاقة استجابية خطية للدواء بين نشاط البلازما والجرعة المعطاة.</p><p dir="RTL">يُعرب عن نشاط البيولوجي <strong>لإنّوهيب<sup>&reg;</sup></strong> في الوحدات الدولية لمضاد &ndash; إكس إيه.</p><p dir="RTL"><strong>دواعي الاستعمال: </strong></p><p dir="RTL">علاج تجلط الأوردة العميقة والانسداد الرئوي:</p><p dir="RTL">الوقاية من جلطة الأوردة العميقة ما بعد الجراحة لدى المرضى الذين أجروا الجراحة العامة وجراحة العظام.</p><p dir="RTL">منع تجلط الدم داخل الخطوط المسارية الوريدية خارج الجسم وعملية غسيل الكلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع الاستعمال </strong></p><p dir="RTL">يحظر من تعاطي الدواء في حال الحساسية المفرطة لأي من مكونات الدواء.</p><p dir="RTL">إن 20000 وحدة دولية مضاد &ndash; إكس إيه / مل المصاغ من <strong>إنّوهيب<sup>&reg;</sup></strong> يحتوي على ميتا ثاني كبريتيت الصوديوم، الذي قد يسبب الحساسية، بما في ذلك الحساسية المفرطة لدى المرضى الميّالين لذلك. في التركيبات المتبقية، دون الكبريتيت، لا وجود للخطورة. الموانع الأخرى هي موانع عامة أو موضعية وجود ميل بؤري للنزيف. ارتفاع ضغط الدم الشديد غير المتحكم فيه. الإصابة الدماغية الحادة. تقيح الشغاف (التهابات بطانة القلب).</p><p dir="RTL"><strong>لقوارير فقط: </strong></p><p dir="RTL">تحتوي قارورة <strong>إنّوهيب<sup>&reg;</sup> </strong>على 10 ملجم / مل من المادة الحافظة كحول البنزيل. يجب مراعاة عدم إعطاء هذه الصيغ للرضيع الخديج وحديثي الولادة ويعود ذلك لخطر ظهور أعراض متلازمة اللهث.</p><p dir="RTL"><strong>الاحتياطات الخاصة </strong></p><p dir="RTL">ينبغي إعطاء <strong>إنّوهيب<sup>&reg;</sup> </strong>بحذر لمرضى القصور الكبدي.</p><p dir="RTL">ينصح بالتحوط في علاج مرضى الفشل الكلوي الحاد (تصفية الكرياتينين &lt; 30 مل / دقيقة).</p><p dir="RTL">ينصح بالحذر في علاج المرضى المسنين الذين يعانون من القصور الكلوي. يجب تقييم وظائف الكلى لدى مرضى القصور الكلوي الحاد (تصفية الكرياتينين &lt; 30 مل / دقيقة)، وينبغي رصد العوامل المضادة لنشاط إكس إيه.</p><p dir="RTL">يجب مراقبة المرضى الذين يتعاطون <strong>إنّوهيب<sup>&reg;</sup></strong> عن كثب تزامناً مع التخدير النخاعي أو التخدير فوق الجافية لأي علامات أو أعراض للإصابات العصبية.</p><p dir="RTL"><strong>التفاعلات</strong></p><p dir="RTL">تعاطي الدواء مع أدوية أخرى ذات تأثير على إيقاف النزيف الدموي، مثل مضادات فيتامين ك وديكستران، قد تعزز من فعالية تأثير مضاد التجلد <strong>لإنّوهيب<sup>&reg;</sup>. </strong></p><p dir="RTL"><strong>الاستعمال أثناء الحمل والرضاعة </strong></p><p dir="RTL">لا تشير بيانات كم عدد (637) من حالات الحمل عن أي مخاطر إضافية من جراء تناول تينزابارين على الحمل أو على صحة الجنين / المولود الجديد. وقد ثبت عدم المرور والوصول إلى خلايا المشيمة من خلال دراستين (2) سريريتين تحليليتين. وقد أوحت البيانات المستمدة من رصد الحركة الدوائية في 55 حالة متتابعة لنساء حوامل تشير إلى خواص الحركة الدوائية في تينزابارين لا تختلف عن تلك الخواص لدى النساء غير الحوامل.</p><p dir="RTL">لا ينصح بتناول تينزابارين لدى النساء الحوامل اللواتي لهن صمامات قلب اصطناعية.</p><p dir="RTL">ينبغي توخي الحذر عند وصف تينزابارين للنساء الحوامل. لا توجد بيانات متاحة تتعلق بالرضاعة.</p><p dir="RTL"><strong>للقوارير فقط </strong></p><p dir="RTL">وقعت حالات &quot;متلازمة اللهث&quot; لدى الخدج عند تناول كميات كبيرة من كحول البنزيل (66-404 مجم / كجم / يومياً). على الرغم من المحتوى المنخفض لكحول البنزيل في قارورة (10 ملجم لكل مل)، وذلك لاحتمال عبوره المشيمة، لهذا لا ينصح باستعمال مستحضرات <strong>إنّوهيب<sup>&reg;</sup></strong> التي تحتوي على كحول البنزيل أثناء الحمل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">علاج تجلط الأوردة العميقة والانسداد الرئوي:</p><p dir="RTL">الجرعة الموصى بها هي 175 وحدة دولية مضاد &ndash; إكس إيه / مل / كجم من وزن الجسم مضاد &ndash; إكس إيه بالحقن تحت الجلد، مرة واحدة يومياً.</p><p dir="RTL">الجرعات العلاجية الوقائية للتجلط لدى المرضى الذين يعانون من مخاطر معتدلة للتجلط (جراحة عامة):</p><p dir="RTL">تُعطى جرعة مقدارها 3500 وحدة دولية مضاد &ndash; إكس إيه / مل بالحقن تحت الجلد، قبل ساعتين من إجراء العملية الجراحية، و 3500 وحدة دولية مضاد &ndash; إكس إيه / مل بعد العملية مرة واحدة يومياً لمدة 7 - 10 أيام.</p><p dir="RTL">الجرعات العلاجية الوقائية للتجلد لدى المرضى الذين يعانون من مخاطر عالية للتجلد (مثل الاستبدال الكلي للورك):</p><p dir="RTL">تُعطى في يوم العملية جرعة مقدارها 4.500 وحدة دولية مضاد &ndash; إكس إيه / مل بالحقن تحت الجلد قبل 12 ساعة من الجراحة، أو 50 وحدة دولية مضاد &ndash; إكس إيه / كجم من وزن الجسم بالحقن تحت الجلد قبل ساعتين من إجراء العملية الجراحية، ومن ثم مرة يومياً إلى أن يتسنى للمريض التحرك ومغادرة الفراش.</p><p dir="RTL">غسيل الكلى على المدى القصير (أقل من 4 ساعات):</p><p dir="RTL">تُعطى جرعة كاملة مقدارها 2000 &ndash; 2500 وحدة دولية مضاد &ndash; إكس إيه داخل الجانب الشرياني من جهاز الاستفزاز) dialyser (أو عن طريق الوريد) عند بداية غسيل الكلى.</p><p dir="RTL">غسيل الكلى على المدى الطويل (أكثر من 4 ساعات):</p><p dir="RTL">تُعطى جرعة كاملة مقدارها 2000 &ndash; 2500 وحدة دولية مضاد &ndash; إكس إيه / مل داخل الجانب الشرياني من جهاز الاستفزاز) dialyser (أو عن طريق الوريد) عند بداية غسيل الكلى، يليها تسريب 750 و. د/ ساعة مضاد &ndash; إكس إيه.</p><p dir="RTL">تضبيط الجرعة: إذا لزم الأمر زيادة أو نقصان في الجرعات الكاملة، فذلك يمكن عمله بإعطاء جرعات من 250 &ndash; 500 وحدة دولية مضاد &ndash; إكس إيه حتى يتم الحصول على استجابة مرضية.</p><p dir="RTL">كبار السن:</p><p dir="RTL">ينبغي تقييم وظائف الكلى مع، على سبيل المثال، صيغة كوكروفت &ndash; غولت لتقدير مستويات تصفية الكرياتينين.</p><p dir="RTL">لا حاجة لخفض الجرعة لدى المرضى المسنين ذوي تقييم وظائف الكلى الطبيعية <strong>(انظر الاحتياطات الخاصة). </strong></p><p dir="RTL">الاختلال الكلوي:</p><p dir="RTL">لا حاجة لخفض الجرعة لدى المرضى الذين يعانون من مستويات تصفية الكرياتينين وصولاً إلى 20 مل / دقيقة، ومع ذلك، يتوخى الحذر عند علاج المرضى الذين يعانون من القصور الكلوي الشديد (تصفية الكرياتينين &lt; 30 مل / دقيقة). <strong>(انظر الاحتياطات الخاصة). </strong></p><p dir="RTL"><strong>الإفراط في الجرعة </strong></p><p dir="RTL">قد يؤدي تجاوز الجرعة العلاجية من <strong>إنّوهيب<sup>&reg;</sup> </strong>إلى نزيف دموي. لا حاجة لإعطاء الترياق حين تعاطي الجرعة الموصى بها. إلا أنه عند تجاوز الجرعة وفي الحالات الطارئة، يمكن عكس تأثر <strong>لإنّوهيب<sup>&reg;</sup></strong> بواسطة تسريب 1% من محلول كريبتات البروتامين داخل الوريد. ينبغي أن تكون جرعات كبريتات البروتامين يعادل 100 وحدة دولية مضاد &ndash; إكس إيه من تينزابارين.</p><p dir="RTL">غسيل اليدين قبل القيام بحقن الدواء. مسح وتنظيف ما حول موضع الحقن بمحلول كحولي وارتكه ليجف. يجب مراعاة &ndash; عدم التدليك (الدعك).</p><p dir="RTL">يجب مواصلة عملية حقن <strong>إنّوهيب<sup>&reg;</sup></strong> تحت الجلد وفقاً للخطوات التالية:</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1033" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:32.85pt;margin-top:12.4pt;width:72.6pt;
 height:48.15pt;z-index:251661312;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" cropbottom="60662f"/>
</v:shape><![endif]-->1- فتح الأنبوبة برفع الغطاء الملون للأنبوبة وثنيه للخلف تماماً وإزالة</p><p dir="RTL">الحقنة (الإبرة).</p><p dir="RTL">تفقد جيداً محتوى الحقنة قبل الاستعمال.</p><p dir="RTL">إذا تمت ملاحظة غيوم أو وجود ترسبات في الدواء يجب عدم استعماله، واستعمال حقنة أخرى.</p><p dir="RTL">قد يتغير لون الدواء للون أصفر أثناء التخزين، إلا أنه يمكن استعمال الدواء إذا كان المحلول صافياً.</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="صورة_x0020_1" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:28.75pt;margin-top:9.7pt;width:72.6pt;
 height:50.1pt;z-index:251654144;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="11520f" cropbottom="48945f"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="97" height="67" src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /></td></tr></tbody></table><p>&nbsp;2- ابعد نظام الأمان بثنيه عن خطاء رأس الحقنة (الإبرة الواقي.</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:28.75pt;margin-top:10.8pt;width:72.6pt;height:55.3pt;
 z-index:251655168;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="17406f" cropbottom="42533f"/>
</v:shape><![endif]-->3- إزالة الغطاء الواقي لإبرة الحقن بدون ثني الإبرة. تعديل وضبط</p><p dir="RTL">الجرعة وفقاً لما وصفه الطبيب. إزالة بقايا المحلول بالضغط عمودياً</p><p dir="RTL">على الغطاس (المكسب) يجب مراعاة عدم سحب الغطاس (المكبس)،</p><p dir="RTL">ولا تضغط فقاقات الهواء للخارج. إذا لم تكن فقاقات الهواء في مكانها الصحيح بواسطة الغطاس (المكسب)، فهنا يتم النقر خفيفاً ويرفق على الحقنة حتى تأخذ الفقاقات مكانها.</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:35.7pt;margin-top:4pt;width:72.6pt;height:49.55pt;
 z-index:251656192;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="29880f" cropbottom="30641f"/>
</v:shape><![endif]-->4- ثني طية جلدية بين الإبهام والسبابة بيد وباليد الأخرى إدخال</p><p dir="RTL">إبرة الحقن عمودياً في طية (ثنية) الجلد، وفي الزاوية الصحيحة.</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1029" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:35.7pt;margin-top:22.2pt;width:72.6pt;height:52.45pt;
 z-index:251657216;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="35887f" cropbottom="24340f"/>
</v:shape><![endif]-->5- حقن الجرعة المطلوبة ببطء إلى داخل الأنسجة الدهنية</p><p dir="RTL">وعلى سبيل المثال الجلد البطني، العضلة الباسطة من جانبي الفخذ،</p><p dir="RTL">أسفل الظهر أو أعلى الذراع، انتظر بضعة ثواني لإعطاء المحلول</p><p dir="RTL">وقتاً للتوزيع قبل إزالة إبرة الحقن وعودة ثنية الجلد لطبيعتها.</p><p dir="RTL">6- مسح وإزالة أي دم بمنديل / منشفة. يجب مراعاة اختيار موضع آخر للحقن في المرة القادمة (على سبيل المثال الانتقال من اليسار لليمين من البطن).</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1031" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:35.7pt;margin-top:58.95pt;width:72.6pt;height:51.8pt;
 z-index:251659264;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="54830f" cropbottom="5463f"/>
</v:shape><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:35.7pt;margin-top:1.35pt;width:72.6pt;height:51.25pt;z-index:251658240;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="49233f" cropbottom="11116f"/>
</v:shape><![endif]-->7- طي (ثني) جهاز الأمن وإعادته لموضعه الطبيعي تحت إبرة الحقن.</p><p dir="RTL">وبالاستناد إلى سطح صلد، على طول إبرة الحقن. ثم الضغط لأسفل</p><p dir="RTL">حتى يتم وضع الإبرة في داخل الجهاز.</p><p dir="RTL"><!--[if gte vml 1]><v:shape
 id="_x0000_s1032" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:35.7pt;margin-top:11.35pt;width:72.6pt;height:54.75pt;
 z-index:251660288;visibility:visible'>
 <v:imagedata src="file:///C:/Users/sahae/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="60134f" cropbottom="-139f"/>
</v:shape><![endif]-->8- يمكن إعادة وضع إبرة الحقن المستعملة في الأنبوبة بتوجيه رأس</p><p dir="RTL">الإبرة نحو أسفل، ويمكن أيضاً رمي إبرة الحقن في مستودع جمع إبر</p><p dir="RTL">الحقن المستعملة. وبهذه الطريقة تكون الأنبوبة أو إبر الحقن المستعملة</p><p dir="RTL">في مكان آمن في مستودع جمع إبر الحقن المستعملة، حيث يمكن تسليمها للمستشفى أو للصيدلي لإتلافها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية</strong></p><p dir="RTL">وكما هو الحال في كل الأدوية، يمكن أن يؤدي مرهم الفيوسيدين<sup>&reg;</sup> لحدوث آثار جانبية، إلا أن هذا لا يشمل جميع الناس. الآثار الجانبية الهامة والتي يجب ملاحظتها جيداً: يجب الحصول على مساعدة طبيبة عاجلة وبوجه السرعة إذا كنت تعاني أي من الأعراض التالية. فقد تعاني من ارتكاس أرجي (تحسسي):</p><p dir="RTL">- صعوبة في التنفس.</p><p dir="RTL">- انتفاخ وتضخم في الوجه والحلق.</p><p dir="RTL">- تطور وظهور طفح جلدي حاد.</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى التي يمكن حدوثها: </strong></p><p dir="RTL">- تأثيرات جانبية غير مألوفة (قد تؤثر على أقل من شخص واحد من بين 100 شخص).</p><p dir="RTL">- تهيجات في مواقع استعمال ودهن الكريم (تشمل آلام، تحرق (شعور بحرق)، شعور بلدغ (لسع) واحمرار جلدي).</p><p dir="RTL">- حكة.</p><p dir="RTL">- طفح جلدي.</p><p dir="RTL">إذا أصبحت أي من التأثيرات الجانبية خطيرة، أو لاحظتم حدوث أي تأثيرات جانبية غير واردة في هذه النشرة الطبية، الرجاء إبلاغ الطبيب أو الصيدلي.</p><p dir="RTL"><strong>إنّوهيب<sup>&reg;</sup> </strong>هو دواء آمن ولا خطورة من احتمال حدوث نزيف دموي عند تناول الجرعات الموصى بها، باستثناء المرضى الذين يعانون من تزايد احتمال حدوث النزيف الدموي (اضطرابات النزيف دموية، نقص الصفيحات الشديد) أو عند العلاج تحت رعاية طبية خاصة.</p><p dir="RTL">وقد أبلغ عن قساح (انتصاب العضو التناسلي) ونخر الجلد في حالات قليلة فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شروط التخزين </strong></p><p dir="RTL">يجب ألا يُخزن بدرجة حرارة تتجاوز الـ 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قوارير تحتوي كل منها على 2 مل </strong></p><p dir="RTL">تينزابارين الصوديوم 10000 وحدة دولية مضاد &ndash; إكس آيه/ مل محفوظة بكحول البنزيل (10 ملجم/ مل).</p><p dir="RTL">تينزابارين الصوديوم 20000 وحدة دولية مضاد &ndash; إكس آيه/ مل محفوظة بكحول البنزيل (10 ملجم/ مل)، مثبتة بميتا ثاني كبريتيت الصوديوم.</p><p dir="RTL"><strong>10 حقن بتعبئة مسبقة مع جهاز أمان إبرة الحقن، تحتوي على 0,25 مل، 0,35 مل أو 0,45 مل. </strong></p><p dir="RTL">تينزابارين الصوديوم 10000 وحدة دولية مضاد &ndash; إكس آيه/ مل</p><p dir="RTL"><strong>حقنتين (2 حقنة) بتعبئة مسبقة مع جهاز أمان إبرة الحقن، تحتوي على 0,5 مل، 0,7 مل أو 0,9 مل. </strong></p><p dir="RTL">تينزابارين الصوديوم 20000 وحدة دولية مضاد &ndash; إكس آيه/ مل، مثبتة بميتا ثاني كبريتيت الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قوارير تحتوي كل منها على 2 مل </strong></p><p dir="RTL">تينزابارين الصوديوم 10000 وحدة دولية مضاد &ndash; إكس آيه/ مل محفوظة بكحول البنزيل (10 ملجم/ مل).</p><p dir="RTL">تينزابارين الصوديوم 20000 وحدة دولية مضاد &ndash; إكس آيه/ مل محفوظة بكحول البنزيل (10 ملجم/ مل)، مثبتة بميتا ثاني كبريتيت الصوديوم.</p><p dir="RTL"><strong>10 حقن بتعبئة مسبقة مع جهاز أمان إبرة الحقن، تحتوي على 0,25 مل، 0,35 مل أو 0,45 مل. </strong></p><p dir="RTL">تينزابارين الصوديوم 10000 وحدة دولية مضاد &ndash; إكس آيه/ مل</p><p dir="RTL"><strong>حقنتين (2 حقنة) بتعبئة مسبقة مع جهاز أمان إبرة الحقن، تحتوي على 0,5 مل، 0,7 مل أو 0,9 مل. </strong></p><p dir="RTL">تينزابارين الصوديوم 20000 وحدة دولية مضاد &ndash; إكس آيه/ مل، مثبتة بميتا ثاني كبريتيت الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق: LEO Pharma A/S, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ آخر مراجعة للنشرة 
أكتوبر 2015

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Innohep
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tinzaparin sodium 10,000 anti-Xa IU/mL

Excipients with known effect:
Benzyl alcohol (10 mg/mL) and sodium (in total < 23 mg/mL). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Vials of 2 mL and 5 mL filled with a colourless or straw-coloured liquid, free from turbidity and from matter that deposits on standing.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of venous thromboembolism in adult patients undergoing surgery, particularly ortho- paedic, general or oncological surgery.</p><p>&nbsp;</p><p>Prophylaxis of venous thromboembolism in non-surgical adult patients immobilised due to acute medical illness including: acute heart failure, acute respiratory failure, severe infections, active can- cer, as well as exacerbation of rheumatic diseases.</p><p>&nbsp;</p><p>Prevention of clotting in extracorporeal circuits and during haemodialysis and haemofiltration in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posology</p><p><u>Prophylaxis of thromboembolic events in adults</u> Administration is by subcutaneous injection.</p><p>&nbsp;</p><p><em>Surgical patients at moderate risk of thromboembolic events:</em></p><p>3,500 anti-Xa IU given SC 2 hours before surgery and then once daily for as long as the patient is considered to be at risk of VTE.</p><p>&nbsp;</p><p><em>Surgical patients at high risk of thromboembolic events e.g. undergoing orthopaedic or cancer surgery:</em></p><p>4500 anti-Xa IU given SC 12 hours before surgery and then once daily for as long as the patient is considered to be at risk of VTE.</p><p>&nbsp;</p><p><em>Non-surgical patients immobilised due to acute medical illness</em></p><p>3,500 anti-Xa IU given SC once daily in patients at moderate risk of VTE, or 4,500 anti-Xa IU given SC once daily in patients at high risk of VTE. Administration should continue for as long as the patient is considered to be at risk of VTE.</p><p>&nbsp;</p><p><u>Neuraxial anaesthesia</u></p><p>Caution is advised when performing neuraxial anaesthesia or lumbar puncture in patients receiv- ing prophylactic doses of Innohep (see section 4.4 regarding neuraxial anaesthesia). If neuraxial anaesthesia is planned, a minimum delay of 12 hours should be allowed between the last prophy- lactic dose and the needle or catheter placement. Innohep should not be resumed until at least 4 - 6 hours after the use of spinal anaesthesia or after the catheter has been removed. Thus, the 2 hours preoperative initiation of thromboprophylaxis with Innohep is not compatible with neurax- ial anaesthesia.</p><p>&nbsp;</p><p><u>Haemodialysis and haemofiltration in adults:</u></p><p>&nbsp;</p><p><em>Duration of 4 hours or less:</em></p><p>A bolus injection of 2,000- 2,500 anti-Xa IU at the start of dialysis/filtration.</p><p>&nbsp;</p><p><em>Duration more than 4 hours:</em></p><p>A bolus injection of 2,500 anti-Xa IU at the start of dialysis/filtration followed by 750 anti-Xa IU/hour a continuous infusion.</p><p>&nbsp;</p><p><em>Dose adjustment:</em></p><p>If necessary, the bolus dose may be increased or decreased gradually in increments of 500 anti- Xa IU until a satisfactory response is obtained. The usual dose is within 2,000 -4,500 anti-Xa IU. In case concomitant transfusion of blood or concentrated red corpuscles, an extra bolus injection of 500&ndash;1,000anti-Xa IU can be administered.</p><p>&nbsp;</p><p><em>Dose monitoring:</em></p><p>Determination of plasma anti-Xa activity can be used to monitor the Innohep dose during haemo- dialysis/haemofiltration. The plasma anti-Xa level should be approximately 0.5 anti-Xa IU/mL one hour after administration.</p><p>&nbsp;</p><p><u>Interchangeability</u></p><p>For interchangeability with other low molecular weight heparins (LMWHs), see section 4.4. <u>Special populations</u></p><p><em>Paediatric population</em></p><p>The safety and efficacy of Innohep in children below 18 years have not yet been established. Currently available data are described in section 5.2, but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>If renal impairment is suspected, renal function should be assessed using a formula based on serum creatinine to estimate creatinine clearance level.</p><p>Use in patients with a creatinine clearance level &lt; 30 mL/minute is not recommended, as dosage in this population has not been established. Available evidence demonstrates no accumulation in pa- tients with creatinine clearance levels down to 20 mL/minute. When required in these patients, Innohep administration can be initiated with anti-Xa monitoring, if the benefit outweighs the risk (see section 4.4 regarding renal impairment).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Innohep should be used in the elderly in standard doses. Precaution is recommended in the treatment of elderly patients with renal impairment. If renal impairment is suspected, see section 4.2 regarding patients with renal impairment and section 4.4 regarding renal impairment.</p><p>&nbsp;</p><p><em>Weight</em></p><p>For patients with very low or very high body weight, 50 anti-Xa IU per kg body weight once daily, may be considered as an alternative to fixed dosing. For surgical patients, the first dose is given SC 2 hours before surgery. The administration should continue once daily for as long as the patient is considered to be at risk of VTE.</p><p>&nbsp;</p><p>Method of administration</p><p>Parenteral products should be inspected visually prior to administration. Do not use if cloudiness or precipitate is observed. The liquid may turn yellow during storage but is still useable.</p><p>&nbsp;</p><p>Innohep is given subcutaneously, for thrombosis prophylaxis in adults. This can be done in ab- dominal skin, the outer side of the thigh, lower back, upper leg or upper arm. Do not inject in the area around the navel, near scars or in wounds.</p><p>For abdominal injections, the patient should be in a supine position, alternating the injections be- tween the left and right side. The air-bubble within the syringe should not be removed. During the injection, the skin should be held in a fold.</p><p>&nbsp;</p><p>For haemodialysis, the dose of Innohep is to be given into the arterial side of the dialyser or in- travenously. The dialyser can be flushed with 500&ndash;1,000 mL isotonic sodium chloride</p><p>(9 mg/mL) containing 5,000 anti-Xa IU Innohep per litre.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Current or history of immune-mediated heparin-induced thrombocytopenia (type II) (see section 4.4).

Active major haemorrhage or conditions predisposing to major haemorrhage. Major haemorrhage is defined as fulfilling any one of these three criteria:
a)	occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome),
b)	causes a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or
c)	leads to transfusion of two or more units of whole blood or red blood cells.

Septic endocarditis.

The multidose vial formulations of Innohep contain 10 mg/mL of the preservative benzyl alcohol. These formulations must not be given to premature babies and neonates due to the risk of gasping syndrome.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neuraxial anaesthesia</u></p><p>Caution is advised when performing neuraxial anaesthesia or lumbar puncture in patients receiving prophylactic doses of Innohep due to the risk of spinal haematomas resulting in prolonged or per- manent paralysis. A minimum delay of 12 hours should be allowed between the last prophylactic dose and the needle or catheter placement. For continuous techniques, a similar delay should be observed before removing the catheter. Moreover, Innohep should not be resumed until at least 4-6 hours after the use of spinal anaesthesia or after the catheter has been removed. Patients should be closely monitored for signs and symptoms of neurological injury.</p><p>&nbsp;</p><p><u>Haemorrhage</u></p><p>Caution is advised when administering Innohep to patients at risk of haemorrhage. For patients at risk of major haemorrhage, see section 4.3. The combination with medicinal products affecting platelet function or the coagulation system should be avoided or carefully monitored (see section 4.5).</p><p>&nbsp;</p><p><u>Intramuscular injections</u></p><p>Innohep should not be administered by intramuscular injection due to the risk of haematoma. Due to the risk of haematoma, concomitant intramuscular injections should also be avoided.</p><p>&nbsp;</p><p><u>Heparin-induced thrombocytopenia</u></p><p>Platelet count should be measured before the start of treatment and periodically thereafter, because of the risk of immune-mediated heparin-induced thrombocytopenia (type II). Innohep must be dis- continued in patients who develop immune-mediated heparin-induced thrombocytopenia (type II), see section 4.3 and 4.8. Platelet counts will usually normalise within 2 to 4 weeks after withdrawal.</p><p>&nbsp;</p><p><u>Hyperkalaemia</u></p><p>Heparin products can suppress adrenal secretion of aldosterone, leading to hyperkalaemia. Risk factors include diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, raised plasma potassium at pre-treatment, concomitant therapy with drugs that may elevate plasma potas- sium, and long-term use of Innohep. In patients at risk, potassium levels should be measured before starting Innohep and monitored regularly thereafter. Heparin-related hyperkalaemia is usually re- versible upon treatment discontinuation, though other approaches may need to be considered if Innohep treatment is considered lifesaving (e.g. decreasing potassium intake, discontinuing other drugs that may affect potassium balance).</p><p>&nbsp;</p><p><u>Prosthetic heart valves</u></p><p>Therapeutic failures have been reported in patients with prosthetic heart valves on full anti-coagu- lant doses of Innohep and other low molecular weight heparins. Innohep is not recommended for use in this population.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Use in patients with a creatinine clearance level &lt; 30 mL/minute is not recommended, as dosage in this population has not been established. Available evidence demonstrates no accumulation in pa- tients with creatinine clearance levels down to 20 mL/minute. When required in these patients, Innohep administration can be used cautiously with anti-Xa monitoring, if the benefit outweighs the risk (see section 4.2). Although anti-Xa monitoring remains a poor predictor of haemorrhage risk, it is the most appropriate measure of the pharmacodynamic effects of Innohep.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Elderly are more likely to have reduced renal function (see section 4.4: Renal impairment); there- fore caution should be exercised when prescribing Innohep to the elderly.</p><p>&nbsp;</p><p><u>Interchangeability</u></p><p>Low molecular weight heparins should not be used interchangeably because of differences in phar- macokinetics and biological activities. Switching to an alternative low molecular weight heparin,</p><p>&nbsp;</p><p>especially during extended use, must be exercised with particular caution and specific dosing in- structions for each proprietary product must be followed.</p><p>&nbsp;</p><p><em>Excipients warnings</em></p><p>The multidose vial formulations of Innohep contain 10 mg/mL of the preservative benzyl alcohol. Benzyl alcohol may cause allergic reactions. Benzyl alcohol may cause toxic and anaphylactoid reactions in infants and children up to 3 years old. High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of ac- cumulation and toxicity (metabolic acidosis).</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per mL, i.e. essentially &lsquo;sodium- free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The anticoagulant effect of Innohep may be enhanced by other drugs affecting the coagulation sys- tem, such as those inhibiting platelet function (e.g. acetylsalicylic acid and other non-steroidal anti- inflammatory drugs), thrombolytic agents, vitamin K antagonists, activated protein C, direct factor Xa and IIa inhibitors. Such combinations should be avoided or carefully monitored (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Anticoagulant treatment of pregnant women requires specialist involvement.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive tox- icity (see section 5.3).</p><p>A large amount of data on pregnant women (more than 2,200 pregnancy outcomes) indicate no malformative nor feto/neonatal toxicity of tinzaparin. Tinzaparin does not cross the placenta. Innohep can be used during all trimesters of pregnancy if clinically needed.</p><p>&nbsp;</p><p><em>Epidural anaesthesia</em></p><p>Due to the risk of spinal haematoma, treatment doses of Innohep (175 IU/kg) are contraindicated in patients who receive neuraxial anaesthesia. Therefore, epidural anaesthesia in pregnant women should always be delayed until at least 24 hours after administration of the last treatment dose of Innohep. Prophylactic doses may be used as long as a minimum delay of 12 hours is allowed be- tween the last administration of Innohep and the needle or catheter placement.</p><p>&nbsp;</p><p><em>Pregnant women with prosthetic heart valves</em></p><p>Therapeutic failures have been reported in pregnant women with prosthetic heart valves on full an- ticoagulant doses of Innohep and other low molecular weight heparins. Innohep cannot be recom- mended for use in this population.</p><p>&nbsp;</p><p><em>Excipients</em></p><p>Innohep vials contain benzyl alcohol. As this preservative may cross the placenta and may cause accumulation and toxicity (metabolic acidosis), {name} formulations without benzyl alcohol (pre- filled syringes) should be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Animal data indicate that Innohep excretion into breast milk is minimal.</p><p>&nbsp;</p><p>It is unknown whether tinzaparin is excreted into human milk. Although oral absorption of low mo- lecular weight heparins is unlikely, a risk to newborns/infants cannot be excluded. In patients at risk, the incidence of venous thromboembolism is particularly high during the first six weeks after</p><p>&nbsp;</p><p>child birth. A decision must be made whether to discontinue breast-feeding or to discontinue/ab- stain from Innohep therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><em>Excipients</em></p><p>Innohep vials contain benzyl alcohol. Due to a risk of accumulation and toxicity (metabolic acido- sis), Innohep formulations without benzyl alcohol (pre-filled syringes) are the preferred choice dur- ing breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no clinical studies with Innohep regarding fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>innohep<sup>&reg;</sup> has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported undesirable effects are haemorrhage events, anaemia secondary to haemorrhage and injection site reactions.</p><p>&nbsp;</p><p>Haemorrhage may present in any organ and have different degrees of severity. Complications may occur particularly when high doses are administered. Although major haemorrhages are uncom- mon, death or permanent disability has been reported in some cases.</p><p>&nbsp;</p><p>Immune-mediated heparin-induced thrombocytopenia (type II) largely manifests within 5 to 14 days of receiving the first dose. Furthermore, a rapid-onset form has been described in patients pre- viously exposed to heparin. Immune-mediated heparin-induced thrombocytopenia (type II) may be associated with arterial and venous thrombosis. Innohep must be discontinued in all cases of im- mune-mediated heparin-induced thrombocytopenia (see section 4.4).</p><p>&nbsp;</p><p>In rare cases, Innohep may cause hyperkalaemia due to hypoaldosteronism. Patients at risk include those with diabetes mellitus or renal impairment (see section 4.4).</p><p>&nbsp;</p><p>Serious allergic reactions may sometimes occur. These include rare cases of skin necrosis, toxic skin eruption (e.g. Stevens-Johnson syndrome), angioedema and anaphylaxis. Treatment should be promptly discontinued at the slightest suspicion of such severe reactions.</p><p>&nbsp;</p><p>The estimation of the frequency of undesirable effects is based on a pooled analysis of data from clinical studies and from spontaneous reporting.</p><p>&nbsp;</p><p>Undesirable effects are listed by MedDRA SOC and the individual undesirable effects are listed starting with the most frequently reported. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><p>Very common (&ge;1/10) Common (&ge;1/100 and &lt; 1/10)</p><p>Uncommon (&ge;1/1,000 and &lt;1/100) Rare (&ge;1/10,000 and &lt;1/1,000)</p><p>Very rare (&lt;1/10,000), unknown (could not be estimated from currently available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common &ge;1/100 and &lt; 1/10</p></td><td style="vertical-align:top"><p>Anaemia (incl. haemoglobin decreased)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ge;1/1,000 and &lt;1/100</p></td><td style="vertical-align:top"><p>Thrombocytopenia (type I) (incl. platelet count de- creased)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Heparin-induced thrombocytopenia (type II) Thrombocytosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ge;1/1,000 and &lt;1/100</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common &ge;1/100 and &lt; 1/10</p></td><td style="vertical-align:top"><p>Haemorrhage Haematoma</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ge;1/1,000 and &lt;1/100</p></td><td style="vertical-align:top"><p>Bruising, ecchymosis and purpura</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ge;1/1,000 and &lt;1/100</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (incl. increased trans- aminases, ALT, AST and GGT)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon &ge;1/1,000 and &lt;1/100</p></td><td style="vertical-align:top"><p>Dermatitis (incl. dermatitis allergic and bullous) Rash</p><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Toxic skin eruption (including Stevens-Johnson syndrome)</p><p>Skin necrosis</p><p>Angioedema Urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Osteoporosis (in connection with long-term treat- ment)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare &ge;1/10,000 and &lt;1/1,000</p></td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common &ge;1/100 and &lt; 1/10</p></td><td style="vertical-align:top"><p>Injection site reaction (incl. injection site haema- toma, haemorrhage, pain, pruritus, nodule, ery- thema and extravasation)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Limited information derived from one study and postmarketing data indicates that the pattern of adverse reactions in children and adolescents is comparable to that in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>Danish Medicines Agency Axel Heides Gade 1</p><p>DK-2300 Copenhagen S</p><p>Homepage: www.meldenbivirkning.dk</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Haemorrhage is the main complication of overdose. Due to the relatively short half-life of Innohep (see section 5.2), minor haemorrhages can be managed conservatively following treatment discon- tinuation. Serious haemorrhage may require the administration of the antidote protamine sulfate.</p><p>Patients should be carefully monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tinzaparin sodium is a low molecular weight heparin of porcine origin with an anti-Xa/anti-IIa ra- tio between 1.5 and 2.5. Tinzaparin sodium is produced by enzymatic depolymerisation of conven- tional unfractionated heparin. Like conventional heparin, tinzaparin sodium acts as an anticoagu- lant by potentiating antithrombin III&rsquo;s inhibition of activated coagulation factors, primarily factor Xa.</p><p>&nbsp;</p><p>The biological activity of tinzaparin sodium is standardised against the current &ldquo;International stand- ards for low molecular weight heparins&rdquo;, and expressed in anti-Xa international units (IU).</p><p>&nbsp;</p><p>The anti-Xa activity of tinzaparin sodium is not less than 70 and not more than 120 IU/mg. The anti-IIa activity of tinzaparin sodium is approximately 55 IU/mg. The characteristic value of mass- average molecular mass of tinzaparin sodium is about 6,500. The mass percentage of chains lower than 2,000 is not more than 10.0 per cent. The mass percentage of chains between 2,000 and 8,000 ranges between 60.0 % and 72.0 % (typical 66%). The mass percentage of chains above 8,000 ranges between 22.0 % and 36.0 %.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The absolute bioavailability based on anti-Xa activity after subcutaneous administration is approximately 90% and time to reach maximal activity is 4-6 hours. The terminal elimination half-life is approximately 3.7 hours. Due to the long half-life of the pharmacological effect for Innohep, once daily administration is sufficient.</p><p>&nbsp;</p><p>Tinzaparin sodium undergoes minor metabolisation in the liver through a depolymerisation and is excreted via the kidneys as an unchanged or almost unchanged form.</p><p>&nbsp;</p><p>The pharmacokinetic activity of Innohep has been studied in pregnant women. Data from sequen- tial pharmacokinetic monitoring of 55 pregnant women indicate that the pharmacokinetic proper- ties do not differ from the pharmacokinetic properties in non-pregnant women. There was a slight, but non-statistically significant drop in the anti-Xa levels as the pregnancy progressed. Some moni- toring of peak anti-Xa levels 4 hours after administration of tinzaparin sodium is recommended in the first weeks of treatment as well as later in the pregnancy.</p><p>&nbsp;</p><p>Following a bolus IV injection of 2,500 anti-Xa IU, administered to dialysis patients, the observed half-life is about 2.5 hours. The pharmacokinetic properties are monitored by anti-Xa activity de- termination. There is a linear connection between plasma anti-Xa and the dose administered.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Preliminary data on the use of tinzaparin suggest that younger children including neonates and infants clear tinzaparin faster and therefore might require higher doses than older children.</p><p>However, data are not sufficient to allow for dosing recommendations, see section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Heparins and low molecular weight heparins (LMWH) are generally only slightly toxic, and this applies for tinzaparin sodium as well. The most important effect observed in studies of acute, sub- acute and chronic toxicity, reproduction toxicity and mutagenicity is haemorrhaging caused by the very high doses administered.</p><p>&nbsp;</p><p>After intramuscular administration of LMWH in animals necrotising haematoma was observed. Osteoporotic effects were revealed in a 12 month study in rats. Animal studies in rats and rabbits did not show a teratogenic potential of LMWH in doses up to 25 mg/kg body weight. Fetuses which were prenatally exposed to 10 mg/kg body weight were found to have lower body weights than controls.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzyl alcohol</p><p>Sodium acetate trihydrate</p><p>Sodium hydroxide</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years

Chemical and physical in use stability has been demonstrated for 28 days at 30°C.

From a microbiological point of view, once opened, the product may be stored for a maximum of 28 days at 30°C. Other in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Multi-dose vials of 2 mL and 5 mL Pack size: 10</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13. February 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>